{"groups":[{"description":"Intravenous Oxaliplatin 130 mg/m\\^2, Day 1 + Oral Capecitabine 750 mg/m\\^2 twice daily Days 1-14.","id":"FG000","title":"Oxaliplatin + Capecitabine"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Thirty-one patients were enrolled onto the study, and 30 patients received study treatment. One patient did not meet eligibility criteria and did not receive any study treatment. One additional patient was removed from the study after one treatment cycle.","recruitmentDetails":"Recruitment Period: November 1, 2004 and July 31, 2007. All participants recruited at UT MD Anderson Cancer Center."}